Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia

Despite improvements in outcomes for children with B- and T-cell acute lymphoblastic leukemia (B-ALL and T-ALL), patients with resistant or relapsed disease fare poorly. Previous studies have demonstrated the essential role of cyclin D3 in T-ALL disease initiation and progression and that targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Bride, Karen L., Hu, Hai, Tikhonova, Anastasia, Fuller, Tori J., Vincent, Tiffaney L., Shraim, Rawan, Li, Marilyn M., Carroll, William L., Raetz, Elizabeth A., Aifantis, Iannis, Teachey, David T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Acute Lymphoblastic Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335101/
https://www.ncbi.nlm.nih.gov/pubmed/34937317
http://dx.doi.org/10.3324/haematol.2021.279410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335101/
https://www.ncbi.nlm.nih.gov/pubmed/34937317
http://dx.doi.org/10.3324/haematol.2021.279410

Ejemplares similares